Literature DB >> 15374880

Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.

George Z Rassidakis1, Marianna Feretzaki, Coralyn Atwell, Ioannis Grammatikakis, Quan Lin, Raymond Lai, Francois-Xavier Claret, L Jeffrey Medeiros, Hesham M Amin.   

Abstract

Anaplastic large cell lymphoma (ALCL) is a highly proliferative neoplasm that frequently carries the t(2;5)(p23;q35) and aberrantly expresses nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). Previously, NPM-ALK had been shown to activate the phosphatidylinositol 3 kinase (PI3K)/Akt pathway. As the cyclin-dependent kinase (CDK) inhibitor p27(Kip1) (p27) is usually not expressed in ALCL, we hypothesized that activated Akt (pAkt) phosphorylates p27 resulting in increased p27 proteolysis and cell cycle progression. Here we demonstrate that inhibition of pAkt activity in ALCL decreases p27 phosphorylation and degradation, resulting in increased p27 levels and cell cycle arrest. Using immunohistochemistry, pAkt was detected in 24 (57%) of 42 ALCL tumors, including 8 (44%) of 18 ALK-positive tumors and 16 (67%) of 24 ALK-negative tumors, and was inversely correlated with p27 levels. The mean percentage of p27-positive tumor cells was 5% in the pAkt-positive group compared with 26% in the pAkt-negative group (P = .0076). These findings implicate that Akt activation promotes cell cycle progression through inactivation of p27 in ALCL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374880      PMCID: PMC1382060          DOI: 10.1182/blood-2004-06-2125

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Authors:  G Z Rassidakis; A H Sarris; M Herling; R J Ford; F Cabanillas; T J McDonnell; L J Medeiros
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Authors:  R Y Bai; T Ouyang; C Miething; S W Morris; C Peschel; J Duyster
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

4.  Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.

Authors:  Naoya Fujita; Saori Sato; Kazuhiro Katayama; Takashi Tsuruo
Journal:  J Biol Chem       Date:  2002-05-31       Impact factor: 5.157

Review 5.  Translocations involving anaplastic lymphoma kinase (ALK).

Authors:  J Duyster; R Y Bai; S W Morris
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

6.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

7.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest.

Authors:  Jiyong Liang; Judit Zubovitz; Teresa Petrocelli; Rouslan Kotchetkov; Michael K Connor; Kathy Han; Jin-Hwa Lee; Sandra Ciarallo; Charles Catzavelos; Richard Beniston; Edmee Franssen; Joyce M Slingerland
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

8.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer.

Authors:  Giuseppe Viglietto; Maria Letizia Motti; Paola Bruni; Rosa Marina Melillo; Amelia D'Alessio; Daniela Califano; Floriana Vinci; Gennaro Chiappetta; Philip Tsichlis; Alfonso Bellacosa; Alfredo Fusco; Massimo Santoro
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

9.  Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections.

Authors:  George Z Rassidakis; Dan Jones; Athanasios Thomaides; Filiz Sen; Raymond Lai; Fernando Cabanillas; Timothy J McDonnell; L Jeffrey Medeiros
Journal:  Am J Clin Pathol       Date:  2002-09       Impact factor: 2.493

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more
  41 in total

1.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

2.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

3.  Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

Authors:  Anna V Galkin; Jonathan S Melnick; Sungjoon Kim; Tami L Hood; Nanxin Li; Lintong Li; Gang Xia; Ruo Steensma; Greg Chopiuk; Jiqing Jiang; Yongqin Wan; Peter Ding; Yi Liu; Fangxian Sun; Peter G Schultz; Nathanael S Gray; Markus Warmuth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

Review 4.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

5.  Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Authors:  Bin Shi; Deeksha Vishwamitra; J Gabrielle Granda; Thomas Whitton; Ping Shi; Hesham M Amin
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

6.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Francisco Vega; L Jeffrey Medeiros; Vasiliki Leventaki; Coralyn Atwell; Jeong Hee Cho-Vega; Ling Tian; Francois-Xavier Claret; George Z Rassidakis
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

7.  PI3K/AKT pathway-mediated regulation of p27(Kip1) is associated with cell cycle arrest and apoptosis in cervical cancer.

Authors:  Shyam Babu Prasad; Suresh Singh Yadav; Mitali Das; Arusha Modi; Soni Kumari; Lakshmi Kant Pandey; Sunita Singh; Satyajit Pradhan; Gopeshwar Narayan
Journal:  Cell Oncol (Dordr)       Date:  2015-03-28       Impact factor: 6.730

8.  Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Authors:  Roberto Piva; Roberto Chiarle; Andrea D Manazza; Riccardo Taulli; William Simmons; Chiara Ambrogio; Valentina D'Escamard; Elisa Pellegrino; Carola Ponzetto; Giorgio Palestro; Giorgio Inghirami
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

9.  Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Authors:  Lei Duan; Ricardo E Perez; Michael Hansen; Steven Gitelis; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.